Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab plus abatacept for plasma cell depletion in rheumatoid arthritis
2024-511536-27-00Phase 2Authorised
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Mar 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daratumumab and abatacept in rheumatoid arthritis (RA), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoints: Injection-related reactions and toxicity after daratumumab, Adverse events and serious adverse events due to investigational medicinal products and 1 more. Planned start Mar 2025; status: authorised.
02
Drugs
daratumumababatacept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2024-511536-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511536-27-00.